Revolution Medicines, Inc. - Common Stock (RVMD)
40.42
-1.49 (-3.56%)
NASDAQ · Last Trade: May 11th, 8:03 PM EDT
Detailed Quote
Previous Close | 41.91 |
---|---|
Open | 41.91 |
Bid | 39.50 |
Ask | 44.00 |
Day's Range | 40.19 - 42.25 |
52 Week Range | 29.17 - 62.40 |
Volume | 1,621,977 |
Market Cap | 4.30B |
PE Ratio (TTM) | -10.08 |
EPS (TTM) | -4.0 |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 2,034,745 |
Chart
About Revolution Medicines, Inc. - Common Stock (RVMD)
Revolution Medicines Inc is a biotechnology company focused on developing innovative therapies to target difficult-to-treat cancers. The company is dedicated to advancing the field of precision medicine, leveraging its proprietary drug discovery platforms to explore new approaches to inhibit cancer-causing pathways. Through rigorous research and clinical trials, Revolution Medicines aims to bring forward novel treatments that not only address the complexities of tumor biology but also improve the effectiveness and safety of cancer care for patients. Their commitment to scientific excellence and collaboration positions them as a forward-thinking leader in the oncology space. Read More
News & Press Releases
Via Benzinga · May 8, 2025
Via Benzinga · May 7, 2025
Revolution Medicines shared Phase 1 data showing zoldonrasib's acceptable safety profile in KRAS G12D mutant solid tumors at AACR 2025.
Via Benzinga · April 28, 2025

Via Benzinga · December 4, 2024
Revolution Medicines Inc. (NASDAQ: RVMD) Climbs to New 52-Week High
Shares of Revolution Medicines, Inc. (NASDAQ: RVMD) traded at a new 52-week high today and are currently trading at $35.52. So far today, approximately 1.12M shares have been exchanged, as compared to an average 30-day volume of 1.43M shares.
Via Investor Brand Network · April 10, 2024

Via Benzinga · December 2, 2024

Via Benzinga · December 2, 2024

Via Benzinga · December 2, 2024

Via Benzinga · July 16, 2024

Via Benzinga · July 16, 2024

Via Benzinga · July 9, 2024

Via Benzinga · July 9, 2024

Undervalued stocks under $50 hold significant appeal, but as every investor knows, value is in the eye of the beholder
Via InvestorPlace · June 8, 2024

https://seekingalpha.com/news/4111624-goldman-sachs-raises-obesity-drug-market-estimate
Via InvestorPlace · June 4, 2024

RVMD stock results show that Revolution Medicines beat analyst estimates for earnings per share the first quarter of 2024.
Via InvestorPlace · May 8, 2024

As of April 12, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Via Benzinga · April 12, 2024

Shares of Ascent Solar Technologies, Inc. (NASDAQ: ASTI) fell sharply during Wednesday’s session after the company announced pricing of a $6 million public offering of shares at $0.14 per share.
Via Benzinga · April 10, 2024

Revolution Medicines announced the publication of a peer-reviewed research paper in "Cancer Discovery" detailing the discovery and preclinical to clinical translation for RMC-6236 on Monday. The company also announced the publication of two peer-reviewed research papers in "Nature" Tuesday. The first paper highlights the discovery and preclinical characterization of RMC-7977, and the second paper highlights the systematic evaluation of RMC-7977 in a wide range of preclinical models of PDAC.
Via Benzinga · April 10, 2024

U.S. stocks were lower, with the Dow Jones index falling over 300 points on Wednesday.
Via Benzinga · April 10, 2024

Via Benzinga · March 8, 2024

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.23 per share on revenue of $477.73 million.
Via Benzinga · February 26, 2024